Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.

Name: Kaimen Rigor review — Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Item: Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Rating: 100
Author: Alpha1

Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Żotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R, EMERALD-1 Investigators

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 3.75★ (Adequate), 0 critical, 1 high issue for “Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.

Read full text (PMC)

DOI

10.1016/S0140-6736(24)02551-0

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/eebee21a-9984-4d4c-a553-28f0596ebb4a" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/eebee21a-9984-4d4c-a553-28f0596ebb4a/badge" alt="Kaimen Rigor review — 3.75★ (Adequate), 0 critical, 1 high issue for “Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

1d3e687d09004b6bb737995724582d5bbb74e0aff7db3547b307f2cf2b8cbc3a

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.

Paper source

Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3.75 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
LinksDead data/code link−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is progression-free survival (PFS), a surrogate for overall survival. The paper does not demonstrate target engagement at the tested dose (no PK/PD or dose-exposure data) and does not cite validated evidence linking PFS to overall survival in this setting. The authors acknowledge that overall survival data are not yet mature and that PFS may be confounded by competing risks.
“The primary endpoint was progression-free survival, by blinded independent central review (BICR), and per RECIST version 1.1, with durvalumab plus bevacizumab versus placebo alone in the intention-to-treat population”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect is a median PFS improvement from 8.2 to 15.0 months (HR 0.77). While statistically significant, the clinical meaningfulness is not anchored to a minimal clinically important difference or a validated threshold for PFS in hepatocellular carcinoma. The paper claims clinical relevance but does not provide an external anchor.
“Median progression-free survival was improved by 6·8 months versus the placebo plus TACE group, which had results that were consistent with previous reports.”
Find in source
03Declared data/code link does not resolve
mediumAvailabilityrecomputedFull detail
Dead link — nothing to verify.
“https://vivli.org/members/enquiries-about-studies-not-listed-on-the-vivli-platform/”
Find in source

Findings by category

01ArithmeticNone found 302OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 105AvailabilityBroken references and links 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 3 randomized controlled trial. The paper demonstrates strong scientific premise, rigorous design, and complete reporting across all eight rigor dimensions, with only minor copyedit issues and a single dead link in the data availability statement.

Both reviewers classified the study as interventional, and this was adopted. The evaluation covered all eight dimensions; several sub-criteria were marked not applicable due to the human clinical trial context (e.g., species/strain, housing, cell line authentication). The statistics verification checked only 2 tests (limited coverage), and the citation check found no retracted or unresolved references. The reproducibility check found 1 dead link among 4 checked.

Numerical inconsistencies

None found

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Checked — nothing surfaced.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Overstated conclusions

3 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

5 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction thoroughly reviews prior studies of TACE, sorafenib, brivanib, orantinib, bevacizumab, and immunotherapies, acknowledging both positive and negative results. The rationale for combining durvalumab and bevacizumab with TACE is logically derived from mechanistic evidence (VEGF and PD-L1 upregulation) and prior trial outcomes. The paper explicitly notes that no prior phase 3 study had shown significant improvement with systemic therapy added to TACE, and the study design addresses this gap.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a strong scientific premise with extensive prior work cited, a clear rationale linking TACE, immunotherapy, and anti-VEGF therapy, and addresses limitations of prior research.

Evidence

“Randomised phase 2 studies with sorafenib, a multikinase inhibitor, have demonstrated the potential benefit of adding systemic therapies to TACE.”

Introduction ¶1Find in source

“TACE increases vascular endothelial growth factor (VEGF) expression in hepatocellular carcinoma tumours, possibly allowing survival of residual tumour tissue after TACE.”

Introduction ¶4Find in source

“However, to date, no phase 3 study has shown significant clinical improvements in any primary endpoint by adding systemic therapy to TACE.”

Introduction ¶3Find in source

PASSReviewer 2· 95% conf

The paper establishes a strong scientific premise by citing prior research on TACE, systemic therapies, and the rationale for combining immunotherapy and anti-VEGF therapy with TACE.

Evidence

“However, to date, no phase 3 study has shown significant clinical improvements in any primary endpoint by adding systemic therapy to TACE.”

Introduction ¶1Find in source

paraphrase[Introduction, paragraph 5]

“These developments in treatment recommendations for advanced hepatocellular carcinoma, alongside the potential synergy theorised between TACE, immunotherapy, and anti-VEGF therapy, indicate the potential for immunotherapy-based combinations to improve outcomes for people with hepatocellular carcinoma amenable to TACE.”

“Due to the aforementioned safety considerations, the study was designed to avoid concurrent bevacizumab and TACE (durvalumab was allowed with TACE, while bevacizumab was only started after completion of TACE).”

Introduction ¶5Find in source

Randomization method (IxRS, blocked, stratified) and unit (participant) are reported. Blinding is described for participants, investigators, and outcome assessors. Power analysis is detailed with planned sample size and event-driven design. Inclusion/exclusion criteria are pre-specified. Outlier handling is addressed through pre-specified analysis populations (ITT, safety) and sensitivity analyses for missing data. Controls are inherent in the placebo arm. Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria; the analysis population and missing-data approach are clearly defined.

Evidence

“Participants were centrally assigned to their study treatment using an interactive voice or web response system (IxRS).”

MethodsFind in source

“Participants, investigators, study centre staff, and those assessing outcomes were masked to treatment assignment until data analysis.”

MethodsFind in source

paraphrase[Methods, Statistical analysis]

“The final progression-free survival analysis was planned for when approximately 287 events from approximately 400 participants had occurred across the durvalumab plus bevacizumab and placebo alone groups (72% maturity), providing more than 99% power to detect a statistically significant difference per the prespecified α allocation.”

PASSReviewer 2· 95% conf

The study design is rigorous with clear randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

“Participants were centrally assigned to their study treatment using an interactive voice or web response system (IxRS).”

MethodsFind in source

“Participants, investigators, study centre staff, and those assessing outcomes were masked to treatment assignment until data analysis.”

MethodsFind in source

paraphrase[Methods, Statistical analysis]

Sex is reported for all participants (135 female, 481 male). Age is reported as median with IQR. Demographics include race and ethnicity. Health status is captured via ECOG performance status and Child-Pugh score. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Sex, age, and demographics are reported; species/strain and housing are not applicable for a human trial.

Evidence

paraphrase[Results, paragraph 1]

“Median age was 65·0 years (IQR 59·0–72·0), 135 (22%) of 616 participants were female, 481 (78%) were male.”

“375 (61%) were Asian, 176 (29%) were White, 22 (4%) were American Indian or Alaska Native, nine (1%) were Black or African American, one (<1%) was native Hawaiian or other Pacific Islander, and 33 (5%) were other races.”

Results ¶1Find in source

PASSReviewer 2· 95% conf

Demographic and clinical characteristics are well reported, including sex, age, race, and disease-related variables.

Evidence

paraphrase[Results, paragraph 1]

“Median age was 65·0 years (IQR 59·0–72·0), 135 (22%) of 616 participants were female, 481 (78%) were male.”

Results ¶1Find in source

paraphrase[Table 1]

“ECOG performance status: 0: 167 (82%) | 1: 37 (18%)”

The paper states that the trial protocol was approved by an Institutional Review Board or Independent Ethics Committee at each site, and written informed consent was obtained. Compliance with Good Clinical Practice, Declaration of Helsinki, and CIOMS guidelines is stated.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethics approval by named IRBs/IECs, informed consent, and regulatory compliance are all reported.

Evidence

paraphrase[Methods, Study design and participants]

“The trial protocol was approved by an Institutional Review Board or Independent Ethics Committee at each site.”

“Written informed consent was obtained from participants (or their legal representatives if the participant lacked capacity to consent) before participation.”

MethodsFind in source

“Good Clinical Practice guidelines of the International Council on Harmonisation, and ethical considerations of the Declaration of Helsinki and Council for International Organisations of Medical Sciences, were followed.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals and consent are adequately reported.

Evidence

paraphrase[Methods, Study design and participants]

“The trial protocol was approved by an Institutional Review Board or Independent Ethics Committee at each site.”

“Written informed consent was obtained from participants (or their legal representatives if the participant lacked capacity to consent) before participation.”

MethodsFind in source

Durvalumab and bevacizumab are named with manufacturer (AstraZeneca implied) and dosing details. The statistical software SAS is identified. Antibodies, cell lines, mycoplasma, and organisms are not applicable as this is a clinical trial without wet-lab assays.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational products (durvalumab, bevacizumab) are identified with doses and regimens; software is identified; other bench resources are not applicable.

Evidence

“Participants in the durvalumab plus bevacizumab group received TACE plus durvalumab (1500 mg intravenously, once every 4 weeks) followed by concurrent durvalumab (1120 mg once every 3 weeks) plus bevacizumab (15 mg/kg intravenously, once every 3 weeks).”

MethodsFind in source

“SAS (version 9.1 or higher) was used for all analyses.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational products (durvalumab and bevacizumab) are adequately identified with dosing and regimen details.

Evidence

MethodsFind in source

“SAS (version 9.1 or higher) was used for all analyses.”

Statistical analysisFind in source

The primary analysis uses stratified log-rank test and Cox proportional hazards model, with HRs and 95% CIs. Exact p-values are given (e.g., p=0.032). Assumptions are handled by design (stratified analysis, sensitivity analyses). Data presentation includes Kaplan-Meier curves and forest plots. Mathematical plausibility is not applicable for large-N continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical tests are named, exact p-values are reported, effect sizes with CIs are provided, software is identified, and data presentation follows clinical trial norms.

Evidence

“Primary and secondary progression-free survival endpoints were analysed using a stratified log-rank test adjusting for TACE modality (drug-eluting bead vs conventional), region (Japan vs the rest of Asia excluding Japan vs other regions), and portal vein invasion (Vp1 or Vp2 [±Vp1] vs none).”

Statistical analysisFind in source

paraphrase[Results, paragraph 3]

“Progression-free survival hazard ratio was 0·77 (95% CI 0·61–0·98; two-sided p=0·032) for durvalumab plus bevacizumab versus placebo.”

paraphrase[Results, paragraph 3]

“Progression-free survival hazard ratio was 0·77 (95% CI 0·61–0·98; two-sided p=0·032).”

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with confidence intervals.

Evidence

paraphrase[Methods, Statistical analysis]

“Primary and secondary progression-free survival endpoints were analysed using a stratified log-rank test adjusting for TACE modality, region, and portal vein invasion. Treatment effects for progression-free survival and time to progression were estimated using a stratified Cox proportional hazards model.”

“Progression-free survival hazard ratio was 0·77 (95% CI 0·61–0·98; two-sided p=0·032) for durvalumab plus bevacizumab versus placebo, and 0·94 (0·75–1·19; two-sided p=0·64) for durvalumab plus placebo versus placebo.”

Results ¶3Find in source

“Progression-free survival hazard ratio was 0·77 (95% CI 0·61–0·98; two-sided p=0·032)”

Results ¶3Find in source

The data sharing statement names Vivli as a managed-access platform and provides URLs for requesting data. This is adequate for patient-level data. Repository deposit and accession numbers are not applicable due to privacy. Code sharing is not applicable as no bespoke code is mentioned.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability statement provides a concrete access route via Vivli and AstraZeneca's policy; repository deposit and accession numbers are not applicable for patient-level data.

Evidence

paraphrase[Data sharing section]

“Data underlying the findings described in this Article can be obtained in accordance with AstraZeneca’s data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure . Data for studies directly listed on Vivli can be requested through Vivli at www.vivli.org.”

PASSReviewer 2· 90% conf

Data availability is adequately described with a concrete access route via Vivli and AstraZeneca's data sharing policy.

Evidence

paraphrase[Data sharing section]

Trial registration number is provided (NCT03778957). Methods are detailed enough for replication. Limitations are explicitly discussed (e.g., regional differences, competing risks). Conclusions are appropriately cautious, noting ongoing overall survival follow-up. Funding and conflicts of interest are disclosed. Reporting guideline adherence is implied by the structured abstract and CONSORT-like flow diagram, though not explicitly named.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial is registered, methods are complete, limitations are discussed, conclusions are proportional, and funding/COI are disclosed.

Evidence

“This study is registered with ClinicalTrials.gov (http://ClinicalTrials.gov) , NCT03778957 (https://clinicaltrials.gov/ct2/show/NCT03778957) , and is closed to accrual.”

AbstractFind in source

“Limitations of this study include that eligibility criteria and treatment practices for TACE differ by region and treatment site, and EMERALD-1 did not stratify randomisation by site or country.”

Discussion ¶7Find in source

“This study was funded by AstraZeneca.”

AcknowledgementsFind in source

PASSReviewer 2· 95% conf

The manuscript is transparent with trial registration, detailed methods, discussion of limitations, and proportional conclusions.

Evidence

paraphrase[Summary, Methods]

“This study is registered with ClinicalTrials.gov, NCT03778957.”

Discussion ¶7Find in source

“In conclusion, the EMERALD-1 study was positive: durvalumab plus bevacizumab plus TACE significantly improved progression-free survival compared with TACE alone, with no new adverse events identified in a heterogeneous population of participants with unresectable hepatocellular carcinoma amenable to embolisation.”

DiscussionFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

1 finding · worst medium

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Dead data/code linksRecomputed

Checked 30 references by DOI: 27 verified — 3 no DOI (shown, not verified).

4 data/code links checked; 3 live, 1 dead.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly typo, consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported; an informed reader should weigh the minor reporting gaps (explicit CONSORT statement, dead link in data availability) and the fact that only a subset of statistics were machine-verified. No erratum is warranted for the core findings, but the dead link and minor copyedit issues could be corrected in a future revision or erratum.

1.
HIGHdata code
Fix the dead link in the data availability statement (reproducibility check found 1 dead link among 4 checked).
A broken link undermines the stated data access route and could prevent readers from obtaining the data.
2.
MEDIUMreporting
Explicitly state adherence to CONSORT reporting guidelines in the Methods or a dedicated section.
Both reviewers noted that reporting guideline adherence is implied but not explicitly stated, which is a minor transparency gap.
3.
MEDIUMreporting
Add a note in the data sharing statement specifying the timeframe and conditions for data availability.
The current statement lacks specific conditions or timelines, which would improve transparency for potential data requesters.
4.
MEDIUMreporting
Clarify in the Discussion that the progression-free survival benefit is based on a single trial and that overall survival data are pending.
This avoids overgeneralization and ensures conclusions are appropriately cautious.
5.
MEDIUMreporting
Consider including a CONSORT flow diagram in the main text (currently referenced as Figure 2) to improve clarity of participant disposition.
A flow diagram in the main text enhances transparency and reader comprehension.
6.
LOWcopyedit
Fix the typo in the Abstract, Findings: change 'With 1 additional follow-up' to 'With additional follow-up'.
The '1' appears to be a typographical error that could confuse readers.
7.
LOWcopyedit
Remove the extra semicolon before the period in Results, paragraph 3: '...two-sided log-rank p=0·64; ).'
Punctuation error that should be corrected for professional presentation.
8.
LOWcopyedit
Add a period at the end of the sentence in Methods, Statistical analysis: '...at the final progression-free survival analysis'.
Missing period at the end of the sentence.
9.
LOWcopyedit
Rephrase the Abstract, Findings sentence for clarity: 'durvalumab plus placebo (n=207), or placebo alone (n=205; ITT population).'
Minor punctuation issue that can be improved for readability.
10.
LOWcopyedit
Ensure consistent use of 'participants' vs 'patients' throughout the manuscript.
Minor stylistic inconsistency noted in the Results, Safety section.

Full text (78,780 chars · analyzed ~95%, head + tail)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.

Read full text (PMC)

DOI

10.1016/S0140-6736(24)02551-0

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/eebee21a-9984-4d4c-a553-28f0596ebb4a" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/eebee21a-9984-4d4c-a553-28f0596ebb4a/badge" alt="Kaimen Rigor review — 3.75★ (Adequate), 0 critical, 1 high issue for “Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

1d3e687d09004b6bb737995724582d5bbb74e0aff7db3547b307f2cf2b8cbc3a

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

3.75 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
LinksDead data/code link−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is progression-free survival (PFS), a surrogate for overall survival. The paper does not demonstrate target engagement at the tested dose (no PK/PD or dose-exposure data) and does not cite validated evidence linking PFS to overall survival in this setting. The authors acknowledge that overall survival data are not yet mature and that PFS may be confounded by competing risks.
“The primary endpoint was progression-free survival, by blinded independent central review (BICR), and per RECIST version 1.1, with durvalumab plus bevacizumab versus placebo alone in the intention-to-treat population”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect is a median PFS improvement from 8.2 to 15.0 months (HR 0.77). While statistically significant, the clinical meaningfulness is not anchored to a minimal clinically important difference or a validated threshold for PFS in hepatocellular carcinoma. The paper claims clinical relevance but does not provide an external anchor.
“Median progression-free survival was improved by 6·8 months versus the placebo plus TACE group, which had results that were consistent with previous reports.”
Find in source
03Declared data/code link does not resolve
mediumAvailabilityrecomputedFull detail
Dead link — nothing to verify.
“https://vivli.org/members/enquiries-about-studies-not-listed-on-the-vivli-platform/”
Find in source

Findings by category

01ArithmeticNone found 302OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 105AvailabilityBroken references and links 06Copyedit5 minor suggestions

Numerical inconsistencies

None found

Checked — nothing surfaced.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Overstated conclusions

3 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

5 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

None found

Checked — nothing surfaced.

Eight Dimensions8 pass

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a strong scientific premise with extensive prior work cited, a clear rationale linking TACE, immunotherapy, and anti-VEGF therapy, and addresses limitations of prior research.

Evidence

“Randomised phase 2 studies with sorafenib, a multikinase inhibitor, have demonstrated the potential benefit of adding systemic therapies to TACE.”

Introduction ¶1Find in source

“TACE increases vascular endothelial growth factor (VEGF) expression in hepatocellular carcinoma tumours, possibly allowing survival of residual tumour tissue after TACE.”

Introduction ¶4Find in source

“However, to date, no phase 3 study has shown significant clinical improvements in any primary endpoint by adding systemic therapy to TACE.”

Introduction ¶3Find in source

PASSReviewer 2· 95% conf

The paper establishes a strong scientific premise by citing prior research on TACE, systemic therapies, and the rationale for combining immunotherapy and anti-VEGF therapy with TACE.

Evidence

“However, to date, no phase 3 study has shown significant clinical improvements in any primary endpoint by adding systemic therapy to TACE.”

Introduction ¶1Find in source

paraphrase[Introduction, paragraph 5]

Introduction ¶5Find in source

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Evidence

“Participants were centrally assigned to their study treatment using an interactive voice or web response system (IxRS).”

MethodsFind in source

“Participants, investigators, study centre staff, and those assessing outcomes were masked to treatment assignment until data analysis.”

MethodsFind in source

paraphrase[Methods, Statistical analysis]

PASSReviewer 2· 95% conf

The study design is rigorous with clear randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

“Participants were centrally assigned to their study treatment using an interactive voice or web response system (IxRS).”

MethodsFind in source

“Participants, investigators, study centre staff, and those assessing outcomes were masked to treatment assignment until data analysis.”

MethodsFind in source

paraphrase[Methods, Statistical analysis]

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Sex, age, and demographics are reported; species/strain and housing are not applicable for a human trial.

Evidence

paraphrase[Results, paragraph 1]

“Median age was 65·0 years (IQR 59·0–72·0), 135 (22%) of 616 participants were female, 481 (78%) were male.”

Results ¶1Find in source

PASSReviewer 2· 95% conf

Demographic and clinical characteristics are well reported, including sex, age, race, and disease-related variables.

Evidence

paraphrase[Results, paragraph 1]

“Median age was 65·0 years (IQR 59·0–72·0), 135 (22%) of 616 participants were female, 481 (78%) were male.”

Results ¶1Find in source

paraphrase[Table 1]

“ECOG performance status: 0: 167 (82%) | 1: 37 (18%)”

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethics approval by named IRBs/IECs, informed consent, and regulatory compliance are all reported.

Evidence

paraphrase[Methods, Study design and participants]

“The trial protocol was approved by an Institutional Review Board or Independent Ethics Committee at each site.”

“Written informed consent was obtained from participants (or their legal representatives if the participant lacked capacity to consent) before participation.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals and consent are adequately reported.

Evidence

paraphrase[Methods, Study design and participants]

“The trial protocol was approved by an Institutional Review Board or Independent Ethics Committee at each site.”

“Written informed consent was obtained from participants (or their legal representatives if the participant lacked capacity to consent) before participation.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational products (durvalumab, bevacizumab) are identified with doses and regimens; software is identified; other bench resources are not applicable.

Evidence

MethodsFind in source

“SAS (version 9.1 or higher) was used for all analyses.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational products (durvalumab and bevacizumab) are adequately identified with dosing and regimen details.

Evidence

MethodsFind in source

“SAS (version 9.1 or higher) was used for all analyses.”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical tests are named, exact p-values are reported, effect sizes with CIs are provided, software is identified, and data presentation follows clinical trial norms.

Evidence

Statistical analysisFind in source

paraphrase[Results, paragraph 3]

“Progression-free survival hazard ratio was 0·77 (95% CI 0·61–0·98; two-sided p=0·032) for durvalumab plus bevacizumab versus placebo.”

paraphrase[Results, paragraph 3]

“Progression-free survival hazard ratio was 0·77 (95% CI 0·61–0·98; two-sided p=0·032).”

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with confidence intervals.

Evidence

paraphrase[Methods, Statistical analysis]

Results ¶3Find in source

“Progression-free survival hazard ratio was 0·77 (95% CI 0·61–0·98; two-sided p=0·032)”

Results ¶3Find in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability statement provides a concrete access route via Vivli and AstraZeneca's policy; repository deposit and accession numbers are not applicable for patient-level data.

Evidence

paraphrase[Data sharing section]

PASSReviewer 2· 90% conf

Data availability is adequately described with a concrete access route via Vivli and AstraZeneca's data sharing policy.

Evidence

paraphrase[Data sharing section]

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial is registered, methods are complete, limitations are discussed, conclusions are proportional, and funding/COI are disclosed.

Evidence

“This study is registered with ClinicalTrials.gov (http://ClinicalTrials.gov) , NCT03778957 (https://clinicaltrials.gov/ct2/show/NCT03778957) , and is closed to accrual.”

AbstractFind in source

Discussion ¶7Find in source

“This study was funded by AstraZeneca.”

AcknowledgementsFind in source

PASSReviewer 2· 95% conf

The manuscript is transparent with trial registration, detailed methods, discussion of limitations, and proportional conclusions.

Evidence

paraphrase[Summary, Methods]

“This study is registered with ClinicalTrials.gov, NCT03778957.”

Discussion ¶7Find in source

DiscussionFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

1 finding · worst medium

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Dead data/code linksRecomputed

Checked 30 references by DOI: 27 verified — 3 no DOI (shown, not verified).

4 data/code links checked; 3 live, 1 dead.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly typo, consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHdata code
Fix the dead link in the data availability statement (reproducibility check found 1 dead link among 4 checked).
A broken link undermines the stated data access route and could prevent readers from obtaining the data.
2.
MEDIUMreporting
Explicitly state adherence to CONSORT reporting guidelines in the Methods or a dedicated section.
Both reviewers noted that reporting guideline adherence is implied but not explicitly stated, which is a minor transparency gap.
3.
MEDIUMreporting
Add a note in the data sharing statement specifying the timeframe and conditions for data availability.
The current statement lacks specific conditions or timelines, which would improve transparency for potential data requesters.
4.
MEDIUMreporting
Clarify in the Discussion that the progression-free survival benefit is based on a single trial and that overall survival data are pending.
This avoids overgeneralization and ensures conclusions are appropriately cautious.
5.
MEDIUMreporting
Consider including a CONSORT flow diagram in the main text (currently referenced as Figure 2) to improve clarity of participant disposition.
A flow diagram in the main text enhances transparency and reader comprehension.
6.
LOWcopyedit
Fix the typo in the Abstract, Findings: change 'With 1 additional follow-up' to 'With additional follow-up'.
The '1' appears to be a typographical error that could confuse readers.
7.
LOWcopyedit
Remove the extra semicolon before the period in Results, paragraph 3: '...two-sided log-rank p=0·64; ).'
Punctuation error that should be corrected for professional presentation.
8.
LOWcopyedit
Add a period at the end of the sentence in Methods, Statistical analysis: '...at the final progression-free survival analysis'.
Missing period at the end of the sentence.
9.
LOWcopyedit
Rephrase the Abstract, Findings sentence for clarity: 'durvalumab plus placebo (n=207), or placebo alone (n=205; ITT population).'
Minor punctuation issue that can be improved for readability.
10.
LOWcopyedit
Ensure consistent use of 'participants' vs 'patients' throughout the manuscript.
Minor stylistic inconsistency noted in the Results, Safety section.

Full text (78,780 chars · analyzed ~95%, head + tail)Analyzed: Aug 15, 2026